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Abstract   29 
 30 
Background 31 
The Global Point Prevalence Survey (Global-PPS) established an international network of hospitals to 32 
measure antimicrobial prescribing and resistance worldwide.  33 
 34 
Methods  35 
Using a standardized surveillance method, detailed data were collected in 2015 from 335 hospitals (H) in 36 
53 countries (C): Europe (25C;215H); Africa (5C;12H), Asia (15C;56H), Americas (6C;43H), Oceania (2C;9H) 37 
for all inpatients receiving an antimicrobial on the day of the survey. We report findings for adult 38 
inpatients. 39 
 40 
Findings  41 
Out of 100,591 inpatients, 86,776 were admitted to adult wards (n=3,315); of which 34.4% (n=29,891 42 
patients) received at least one antimicrobial. Among 48,436 antimicrobials in the entire survey, 41,213 43 
were used in adult wards of which 89.6% antibacterial agents (ATC J01) for systemic use.  44 
The top three antibiotics included penicillin beta-lactamase inhibitor combinations (highest in Western 45 
Europe:33.3% and Northern Europe:28.6%); third-generation cephalosporins (highest in Eastern 46 
Europe:49.4% and Western and Central Asia:25.0%); and fluoroquinolones (highest in Northern 47 
America:19.1%). Carbapenems were most frequently prescribed in Latin America and Western and 48 
Central Asia (9.0%). Among 19.8% patients with targeted treatment, 5.9% (range:2.8% in Africa to 15.2% 49 
in Latin America) received an antibiotic targeting a multidrug resistant organism. Latin America and East 50 
and Southern Asia reported the highest number of patients having at least one healthcare associated 51 
infection (11.9% and 10.1% respectively). Overall, the reason for treatment was recorded in 76.9% and a 52 
stop/review date in 38.3% of antimicrobial prescriptions. Local antibiotic guidelines were missing in 53 
19.2% of recorded diagnosis and guideline compliance was 77.4%.  54 
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 55 
Interpretation  56 
This Global-PPS demonstrated that worldwide surveillance can be accomplished with voluntary 57 
participation. It  uniquely provided quantifiable measures to assess and compare quantity and quality of 58 
antibiotic prescribing and resistance in hospitalized patients worldwide (www.global-pps.com). These 59 
data serve to improve quality of antibiotic prescribing through education and practice changes. The 60 
Global-PPS is particularly useful for Low-Middle-Income-Countries for which no tools are available to 61 
monitor antibiotic prescribing in hospitals. 62 
 63 
Funding 64 
bioMérieux provided unrestricted funding support for the survey. 65 
 66 
67 
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Research in context 68 
 69 
Evidence before this study 70 
Surveillance systems monitoring antimicrobial use and resistance are the cornerstone to successfully 71 
implement sustainable antimicrobial stewardship programmes. They are needed to enhance decision-72 
making and assess the impact of interventions. A Point Prevalence Survey (PPS) is a well demonstrated 73 
method which has shown its applicability and benefit in European hospitals and beyond.  74 
 75 
Added value of this study 76 
The project, called the Global-PPS, assessed the prevalence of antimicrobial use and resistance 77 
worldwide. The Global-PPS offered a simple protocol and tool for data entry and immediate feedback 78 
enabling direct benchmarking with other (primary, secondary or tertiary care) hospitals and wards (e.g. 79 
Intensive Care, haematology/oncology, transplant, pneumology, surgery), by country and region. 80 
Hospitals in Low and Middle Income Countries (LMIC) were for the first time able to measure and 81 
compare antimicrobial use patterns at local and regional level. The Global-PPS allows to share best 82 
practises and raise awareness of inappropriate antimicrobial prescribing. Tangible quantifiable quality 83 
indicators were offered to improve antibiotic prescribing at hospital level. Participants became part of a 84 
unique and strong network supporting them in the process of data collection, -entry, -analysis, 85 
communication of their results.  86 
 87 
Implications of all the available evidence 88 
The WHO has developed the Global Antimicrobial Surveillance System (GLASS) that provides countries 89 
with a standardized approach for collecting, analyzing, and sharing data on AMR. The Global-PPS can 90 
complement this by providing a validated method for measuring the quality of antimicrobial prescribing 91 
and the impact of interventions to improve antimicrobial prescribing. Governments can use this to 92 
support the antimicrobial stewardship framework as part of their WHO National Action Plans, whereas 93 
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the Interagency Coordination Group (IACG) on AMR of the United Nations could use it for international 94 
mapping of antimicrobial prescribing and resistance in hospitals, and for building a sustainable hospital 95 
surveillance framework, focusing on LMIC. 96 
 97 
 98 
99 
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Introduction 100 
 101 
The need for information and data related to the quantity and quality of antimicrobial prescribing has 102 
been identified as one of the key barriers in the successful development and implementation of 103 
antimicrobial stewardship programmes internationally.1 Surveillance systems to monitor antimicrobial 104 
use and resistance are needed to enhance decision-making and assess the impact of interventions.2, 3 105 
Moreover, audit and feedback of prescribing practices complements and enhances4 other core 106 
stewardship interventions.5, 6 107 
 108 
The Global Point Prevalence Survey of Antimicrobial Consumption and Resistance (Global-PPS) was 109 
developed to further build on three point-prevalence surveys (PPS) carried out by the European 110 
Surveillance of Antimicrobial Consumption (ESAC) project between 2006 and 2009.7, 8 Several studies on 111 
the applicability and benefits of a PPS of antimicrobial use demonstrated their value in a range of 112 
European hospitals.8-11 The ESAC-PPS methodology was adapted for the European Centre for Disease 113 
Prevention and Control (ECDC) PPS of healthcare-associated infections and antimicrobial use in acute 114 
care hospitals (ECDC-PPS)12 as well as for the Antibiotic Resistance and Prescribing in European Children 115 
(ARPEC-PPS) project that focused on antimicrobials administered to paediatric and neonatal patients 116 
worldwide.13-16  117 
Following the 4th World Healthcare-Associated Infections and Antimicrobial Resistance Forum on,2 118 
bioMérieux decided to support a project to assess the international prevalence of antimicrobial use and 119 
resistance, called the Global-PPS, prioritizing countries with limited resources, support and expertise.17  120 
 121 
We report on the first Global-PPS conducted in 2015. The current paper describes antibiotic prescribing 122 
practises among hospitalized patients admitted to adult wards only (hereafter called “adult inpatients”), 123 
in order to determine the variation in quantity and quality of antimicrobial prescribing and resistance 124 
rates across continents.  125 
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 126 
Materials and methods 127 
 128 
Countries and hospitals 129 
 130 
Any hospital was welcome to join the ad hoc Global-PPS network.  Promotion of the study was done 131 
through existing ESAC- and ARPEC-PPS hospital networks, during the 2014 ECCMID congress 132 
(http://2014.eccmid.org/), through the aid of bioMérieux subsidiaries and members of the HAI/AMR 133 
Forum.17   134 
The Global-PPS was first piloted in October-November 2014 in 33 hospitals worldwide. Key amendments 135 
following this pilot included improvements to the Global-PPS software tool, not protocol amendments. 136 
The full Global-PPS was conducted between January and September 2015. The data of hospitals 137 
successfully participating in the pilot Global-PPS (n=18) were transferred for inclusion in the full Global-138 
PPS data-set for final analysis. As such, we finally included 335 hospitals from 53 countries belonging to 139 
the five United Nation (UN) regions (Africa, Americas, Asia, Europe and Oceania).18 Depending on the 140 
number of hospitals participating, countries were grouped into UN sub-regions. For the Americas, Latin 141 
America and the Caribbean (hereafter called Latin America because of lack of data on the Caribbean) and 142 
Northern America were defined. For Asia, Southern, Eastern and South-eastern Asia (hereafter called 143 
East and Southern Asia) on one side and Western and Central Asia on the other side were grouped 144 
together. For Europe, four sub-regions (i.e. Eastern, Northern, Southern, Western) were defined.18 145 
Details on the participating countries and the number and type of hospitals is available as supplementary 146 
material (Appendix I). Hospitals were classified according to primary, secondary, tertiary (including 147 
infectious diseases hospitals) and paediatric hospitals, as previously defined by the European Centre for 148 
Disease Prevention and Control (ECDC).19 Overall, five main ward types were defined for adult and 149 
paediatric wards separately: medical wards; surgical wards; intensive care units; haematology/oncology 150 
wards and transplant (bone marrow transplant/solid) medical wards. For adult wards we also specified 151 
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pneumology medical wards. Neonatal wards included neonatal intensive care units and general neonatal 152 
medical wards. 153 
 154 
Data collection 155 
 156 
As detailed in the protocol (Appendix II), each ward had to be surveyed once within the fixed time 157 
period. The one-day cross sectional PPS included all inpatients admitted in the ward at 8:00 am the day 158 
of the survey. Data collection was performed using a ward (recording of denominators) and a patient 159 
(recording of numerators) paper form. Definitions on the different variables are available as 160 
supplementary material in appendix II and III. In summary, for each patient receiving at least one 161 
antimicrobial, mandatory data included information on patient characteristics, received antimicrobial 162 
agents and details on the diagnosis and indication according to predefined lists (Appendix III). Four main 163 
types of indications categorized into two major categories were used. The first included therapeutic 164 
antimicrobial prescribing for community-acquired (CAI) and health-care associated infections (HAI). A HAI 165 
was defined as an infection whereby symptoms started 48 hours after admission to the hospital. The 166 
second category included antimicrobial prescribing for surgical and medical prophylaxis. Retrospective 167 
information on surgical prophylaxis was captured in the previous 24 hours of the surgery indicating 1 168 
dose, multiple doses in 1 day or multiple doses for more than one day. Additional antimicrobial quality 169 
indicators included 1) the diagnosis being documented in the patient’s notes at the start of treatment; 2) 170 
the antibiotic prescription (choice) being compliant with local guidelines and 3) if a stop or review date of 171 
the antimicrobial prescription was documented in the notes. Additionally, empiric or targeted treatment 172 
(based upon microbiology data from a relevant clinical specimen (e.g., blood, sputum, etc.,) [excluding 173 
screening tests]) was recorded. If the treatment choice was determined by available microbiology data, 174 
the participant could indicate if it targeted one of the 9 multidrug-resistant organisms as described in 175 
Table 6 and appendix III. Finally, information included whether biomarker data (C-reactive protein (CRP), 176 
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procalcitonin (PCT) or any other biomarker) were used in supporting the decision to prescribe. 177 
Denominators included the total number of patients present on the ward census at 8 am.  178 
 179 
Antimicrobials included antibiotics for systemic use (J01), antimycotics (J02) and antifungals (D01B) for 180 
systemic use, drugs to treat tuberculosis (J04A), oral antibiotics prescribed as intestinal anti-infectives 181 
(A07AA; e.g. oral vancomycin), nitroimidazole derivatives (P01AB), neuraminidase inhibitors (J05AH) and 182 
antimalarials (P01B). All antimicrobials were online automatically classified according to the standardized 183 
and internationally recognized WHO Anatomical Therapeutic Chemical (ATC) classification system 184 
classifying drugs based on their main therapeutic use (WHO, version 2014).20  185 
The protocol (supplementary material, appendix III) mentioned that no discussion or personal judgment 186 
on the appropriateness, or lack thereof, of antibiotic prescribing should be entertained during the survey. 187 
Data were inputted into the freely available Global-PPS program, a web-based application for data-entry, 188 
validation and reporting. A helpdesk and several supplementary documents such as a frequently asked 189 
questions (FAQ) list were freely available to support the participants.  190 
Data validation included several online in-built checks providing errors and warnings that had to be 191 
managed by the user in order to download a real-time feedback report (see discussion: study strengths). 192 
Since total inpatient inclusion at the hospital level was requested but not mandatory, the participants had 193 
to report whether they surveyed the whole hospital or not (i.e. a check on completeness of data). The 194 
software was further designed to avoid missing and erroneous data-entry in the numerator such as 195 
inconsistencies between the indication and the diagnosis (e.g. an antibiotic given for prophylactic use but 196 
prescribed for sepsis), extremely high total daily dose, double entry of the same substance; as well as 197 
denominator error avoidance (see also appendix II, data validation). In addition, all hospitals with an 198 
overall antibiotic prevalence of more than 70% were individually contacted in order to confirm the 199 
described prevalence.  200 
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All data were completely anonymized within the database and safeguarded at the University of Antwerp, 201 
Belgium. However, all data remained the property of the hospital. Since participation was exclusively on 202 
a voluntary basis,  results were not intended to be representative for a country or region. Depending on 203 
the countries’ legal requirements, hospitals had to comply with local ethical approval. A data privacy 204 
excerpt document was available for this purpose. Informed consent was not needed because the survey 205 
did not require direct involvement or contact with the patient, treatment nor other intervention.  206 
 207 
Data analysis 208 
 209 
For the final analyses, 303 hospitals were eligible for inclusion: 22 pediatric hospitals (see appendix I) as 210 
well as another three hospitals which did not report data on adult wards were removed from analyses. 211 
Also another 7 hospitals were excluded due to unsolved denominator issues.  212 
This paper focusses on prescribing patterns of antibiotics for systemic use (ATC J01) and is reported as 1) 213 
the number of treated patients, 2) the number of therapies and 3) the number of prescriptions. Therapy 214 
was defined as one treatment (received at least one antibiotic) per diagnosis. A prescription was defined 215 
as the use of one substance in one route of administration. Antimicrobial prescribing rates are expressed 216 
as a percentage of the patients on antimicrobials, or as a percentage of all antibiotic or antimicrobial 217 
prescriptions (proportional use), means and/or ranges aggregated at UN regional level,18 by ward type 218 
and indication. We ranked the number of antibiotics accounting for 90% and 75% of (antibiotic) drug 219 
utilization (DU90% and DU75%). Antibiotic resistance patterns are expressed as the proportion of 220 
patients receiving at least one antibiotic targeting at least one resistant micro-organism out of all 221 
patients for which an antimicrobial result (targeted treatment) was available. 222 
 223 
Results 224 
 225 
General overview 226 
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 227 
The final 2015 Global-PPS dataset included 45 primary care (6,264 patients, 6.2%), 131 secondary care 228 
(34,571 patients, 34.4%), 111 tertiary care (51,051 patients, 50.8%), 22 pediatric hospitals (4,091 229 
patients, 4.1%) as well as 19 infectious diseases or specialized hospitals (4,614 patients, 4.6%) (see 230 
Appendix I). The number of beds of participating hospitals ranged from 16 to 2,500 beds (82 hospitals fell 231 
below P25=153 beds; P50=293 beds; P75=520 beds; 33 hospitals fell above P90=817 beds of which 19 232 
had a bed capacity of >1,000 beds). We collected data on 100,591 patients admitted to 4,031 wards of 233 
which 3,315 adult wards accounting for 86,776 patients. Overall, 52.6% of treated patients were males 234 
(range 45.6% in Northern America to 57.3% in Eastern Europe).  235 
Out of 48,436 antimicrobial prescriptions, 41,213 were prescribed on adult wards. Antibacterials for 236 
systemic use (ATC code J01) represented 89.6% (N=43,391), followed by antimycotics and antifungals for 237 
systemic use (J02 and D01BA, 4.3%, N=2,073), drugs to treat tuberculosis (J04A, 2.3%, N=1136), 238 
nitroimidazole derivatives (P01AB, 1.9%, N=929), antibiotics prescribed as intestinal anti-infectives 239 
(A07AA, 1.6%, N=781) and neuraminidase inhibitors (J05AH, 0.3%, N=126).  240 
Antimicrobial use rates among participating hospitals varied between continents (range: 31.9% in Europe 241 
to 50.0% in Africa) and ward types (range: 29.0% in medical wards to 77.0% in transplant (BMT/solid) 242 
medical wards) (Table 1). 243 
 244 
Antibiotic drug utilization  245 
 246 
In total, 36,792 antibacterials for systemic use were used in patients admitted to adult wards on the day 247 
of the survey, including 139 different agents (Table 2). The DU90% for East and Southern Asia comprised 248 
31 antibacterials, while this was much lower for Africa and for Eastern Europe (15 and 13 respectively). 249 
The combination of penicillins with a beta-lactamase inhibitor were the most commonly prescribed class 250 
(20.1%, mainly amoxicillin with beta-lactamase inhibitor (11.4%) and piperacillin with beta-lactamase 251 
inhibitor (7.7%) of total use of antibiotics). The second and third most commonly prescribed antibiotics 252 
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were third-generation cephalosporins (14.1%, mainly ceftriaxone (11.0%)) and fluoroquinolones (12.3%, 253 
mainly ciprofloxacin (6.8%) and levofloxacin (4.1%)). Complementary to Table 2, a supplementary figure 254 
(appendix IV) shows the most commonly prescribed subgroups of antibiotics by UN region. 255 
 256 
Antibiotic prescribing by indication  257 
 258 
The top 5 indications accounted for 45.9% of treated patients. Pneumonia was overall the most common 259 
indication (19.2% of all treated patients). The next most common reasons were skin and soft tissue 260 
infections (9.0%), intra-abdominal infections (7.0%), lower urinary tract infections (cystitis, 6.0%) and 261 
upper urinary tract infections (pyelonephritis, 4.7%). Table 3 summarizes the most common indications 262 
for treatment in patients admitted to adult wards, by UN region.  263 
 264 
Therapeutic prescribing  265 
 266 
Table 4 compares the number of prescribed antibacterials (J01) by indication and type of treatment. 267 
Overall, most antibiotics were prescribed for community-acquired infections (CAI) (45.6%). Targeted 268 
prescribing was more common for HAI (36.9%). 269 
The overall prevalence of adult inpatients treated with antibacterials (J01) for at least one HAI was 8.4% 270 
(n=7,278). Lowest rates were found in Eastern Europe (2.8%), followed by Southern Europe (7.5%), 271 
Western Europe (7.7%), Western and Central Asia (8.7%), Northern Europe (8.8%), Oceania (8.9%), 272 
Northern America (9.6%), East and Southern Asia (10.1%) and Latin America (11.9%). The most frequent 273 
reported indications (see online Appendix III, page 7, supplementary data collection forms for type of 274 
indication) were non-intervention related or other HAI (4.2%), followed by post-operative surgical site 275 
infections (1.6%). 276 
 277 
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The most prescribed antibiotics for a HAI were penicillins with a beta-lactamase inhibitor (24.8%) of 278 
which piperacillin and beta-lactamase inhibitor accounted for 14.6% (highest use in Northern Europe; 279 
24.2% and Northern America; 15.2%) and amoxicillin and beta-lactamase inhibitor for 8.9% (highest use 280 
in Western Europe; 17.7% and Northern Europe; 11.9%). Fluoroquinolones were the second most 281 
prescribed (12.8%), with highest use in Eastern Europe (24.4%; mainly ciprofloxacin, 15.9% and 282 
moxifloxacin, 7.3%), Northern America (18.9%; mainly levofloxacin, 11.8% and ciprofloxaxin, 7.0%) and 283 
lowest in Northern Europe (5.2%). Carbapenems, mainly meropenem, were the third most frequently 284 
prescribed antibiotic class accounting for 12.2% of worldwide antibiotic use for a HAI with highest use 285 
observed for Western and Central Asia, Africa and Latin America (all 20%). The fourth most frequently 286 
prescribed were glycopeptides (mainly vancomycin) with highest use in Latin and Northern America 287 
(18.1% and 13.8% of total antibiotic use for HAI, respectively) (Figure 1). 288 
 289 
The most commonly prescribed antibiotics for CAI were penicillins with a beta-lactamase inhibitor 290 
(29.2%) of which amoxicillin and beta-lactamase inhibitor accounted for 16.3% (highest use in Western 291 
Europe; 33.8% and Northern Europe; 14.5%) and piperacillin and beta-lactamase inhibitor for 7.7% 292 
(highest use in Northern Europe; 14.0% and Northern America; 12.7%). Third-generation cephalosporins 293 
were second most common prescribed (15.5%, mainly ceftriaxone) with highest rates observed in 294 
Eastern Europe, Latin America and Western and Central Asia (52.0%, 30.1%, 27.0% of total antibiotic use 295 
for treatment of CAI). Fluoroquinolones ranked third (14.0%) and were frequently prescribed for a CAI in 296 
Northern America (20.1%, mainly levofloxacin) and Southern Europe (19.0%, mainly ciprofloxacin). Figure 297 
2 shows the most commonly prescribed antibiotics to treat a CAI, by region. 298 
 299 
Prophylactic prescribing  300 
 301 
On average, 26.6% (range: 16.6% in Northern America to 41.5% in Eastern Europe) of adult patients 302 
receiving antibiotics were administered at least one antibiotic for prophylaxis. The overall mean 303 
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prevalence of surgical prophylaxis was 17.8% (Table 4). Cefazolin was the most commonly prescribed 304 
antibiotic for surgical prophylaxis (27.5%) with highest prescribing rates observed for Oceania (64.5% of 305 
total surgical prophylactic prescribing), Northern America (62.4%) and Western Europe (57.7%). 306 
Ceftriaxone was most commonly prescribed in Eastern Europe, Southern Europe and Africa (39.5%, 307 
28.0% and 27.7% respectively). Prolonged surgical prophylaxis (>1 day) was very common in all regions, 308 
ranging from 40.6% in Oceania to 85% and 86.3% in Southern and Eastern Europe. 309 
 310 
The overall mean prevalence of medical prophylaxis was 7.4% (Table 4). Many different antibiotics were 311 
used for medical prophylaxis with sulfamethoxazole/trimethoprim being predominant worldwide 312 
(highest use in Oceania and East and Southern Asia, 63.4% and 56.0% of total medical prophylactic 313 
prescribing respectively). Ceftriaxone was most commonly prescribed in Eastern Europe, Southern 314 
Europe and Western and Central Asia (54.2%, 16.9% and 16.9% respectively).  315 
 316 
Quality indicators of antibiotic prescribing  317 
 318 
Table 5 provides an overview of all selected antimicrobial quality indicators by region. The stop/review 319 
date was poorly documented (overall 38.3% of antimicrobial prescriptions). 320 
 321 
Antibiotic treatment based on microbiology data  322 
 323 
Among 29,891 treated patients, 1,769 (19.8%) received a targeted antibacterial (J01) treatment (range: 324 
7.8% in Eastern Europe to 26.5% in Latin America), 5.9% of whom received the treatment targeting at 325 
least one multidrug-resistant organism (Table 5). Overall, 60% of these patients received antibiotics 326 
targeting gram negative bacteria (GNB) with highest proportional numbers observed in Eastern Europe. 327 
Only in Northern America, a higher proportion of patients received targeted treatment against Gram-328 
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positive bacteria. Table 6 shows the prevalence of patients receiving targeted treatment against resistant 329 
bacteria by UN region.  330 
 331 
Discussion 332 
 333 
We demonstrated the feasibility of conducting the Global-PPS, which focused on antibiotic prescribing 334 
and resistance, with a simple and affordable method on an international scale. Many hospitals were able 335 
to assess antibiotic prescribing patterns and collect information on antibiotic resistance  in their hospital 336 
for the first time. This is essential for developing antimicrobial stewardship programs. Other PPSs have 337 
been conducted successfully in High Income Countries (HIC) of the European Union and the United States 338 
of America21, 22, but this simple Global-PPS tool also allowed the participation of a large number of 339 
hospitals in Low and Middle Income Countries (LMIC) to collect information on antimicrobial use and 340 
resistance. 341 
 342 
We found substantial differences in the prevalence of antibiotic prescribing between and within regions 343 
or countries with the highest prevalence found in Africa (50.0%; country range 27.8%-74.7%) and the 344 
lowest in Eastern Europe (27.4%; country range 23.7%-27.8%). The overall prevalence for Europe (31.9%; 345 
range: 23.7% in Bulgaria to 62.0% in the Former Yugoslav Republic of Macedonia (results not show)) was 346 
comparable with the weighted prevalence of previous PPS in Europe in 2011-2012 (32.6%; range: 21.4% 347 
in France to 54.7% in Greece)21, but lower as compared to the PPS conducted in 183 US hospitals in 2011 348 
(49.9%; CI 49.0%-50.9%).22 Amoxicillin with beta-lactamase inhibitor was found to be the most frequently 349 
prescribed antibiotic in this survey, which is related to its high prescribing rates in Western Europe 350 
(25.6%), mainly represented by Belgian hospitals (Table 2). Except for Western Europe, this is in line with 351 
the ECDC-PPS in 2011-2012 whereby this agent represented on average 11.% of all antimicrobial 352 
agents.21 The third-generation cephalosporins, mainly ceftriaxone, ranked second, and this was due to 353 
the high prescribing rates observed in Asia, Latin America, Southern and Eastern Europe; both for CAI 354 
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and HAI. The high use of ceftriaxone in these regions of the world may indicate that at least a proportion 355 
of this prescribing may be inappropriate. Fluoroquinolones ranked third among antibiotics prescribed 356 
during this global PPS, due to the high use of levofloxacin in hospitals in Northern America and East and 357 
Southern Asia (mainly for pneumonia in both cases), and the high use of ciprofloxacin, mainly for cystitis 358 
in Western Europe and various indications elsewhere in Europe. Striking differences of levofloxacin use 359 
were found in the Americas (12.8% in Northern America versus 1.2% in Latin America) and Asia (7.4% in 360 
East and Southern Asia versus <1.0% in Western and Central Asia) (Table 2). There may be differences in 361 
cost or access to fluoroquinolones that preclude their use in certain locations which may vary 362 
substantial, among and within countries. We also speculate that these differences could be due to 363 
marketing strategies and/or regulation of antibiotics in these regions. Remarkably high vancomycin use 364 
was noted in Northern and Latin American hospitals. This high vancomycin use can be explained by high 365 
MRSA rates reported for American hospitals,23 which is in line with the high percentage of patients with 366 
targeted treatment against MRSA infections in this Global-PPS (table 6). Carbapenems (mainly 367 
meropenem) were widely prescribed in Latin America and Asia. These high prescribing rates are most 368 
likely due to the high rates of infections caused by ESBL-producing Gram-negative bacteria, which has 369 
been reported in previous surveillance studies,24-26 and which is in line with the observed rates in our 370 
Global-PPS (table 6).  371 
 372 
The most frequent indication for antibiotic therapy worldwide was pneumonia, followed by urinary tract 373 
infections (UTI), combining upper and lower UTI’s. We need more in-depth analyses to find out the 374 
proportion of healthcare associated ESBL UTI’s. There appeared to be high proportion of prophylaxis for 375 
a range of indications, but unusually high prophylactic use for gastro-intestinal infections in Western and 376 
Central Asia. Further research is warranted in order to understand the reasons for this. 377 
 378 
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Our study investigated five antibiotic quality indicators to identify areas of inappropriate antibiotic 379 
prescribing. These can easily be used to set benchmarks for quality improvement of antibiotic use in 380 
hospitals.10  381 
The first indicator referred to the documentation of the reason for prescription in the patient notes. This 382 
indicator ensures communication of diagnosis and treatment among clinicians and other healthcare 383 
providers, allows prescription stop or review dates and other interventions such as de-escalation. In 384 
Northern and Western Europe, America and Oceania, the outcome of this indicator is comparable to the 385 
2009 ESAC-PPS conducted among European adults (80%).8 Lower scores were found for Eastern (64%) 386 
and Southern European (70%), African (70%) and Asian hospitals (73%).  387 
The second indicator refers to the formal procedure for a physician or other staff member to review the 388 
appropriateness of an antimicrobial administered at or after 48 hours from the initial order (post-389 
prescription review).27 It refers to the existence of a policy or agreed intervention preventing 390 
unnecessarily long antibiotic courses and ensures that the chosen antibiotic and its route of 391 
administration is still appropriate. Such a policy has an impact on selection pressure, prevention of 392 
adverse effects such a drug related toxicity and ecological damage leading to C.difficile  infection. In less 393 
than one third of antimicrobials prescribed in Southern Europe, Western and Central Asia and Oceania, a 394 
stop/review data was recorded. In other areas, less than half of all prescriptions included a stop/review 395 
date. These data indicate the need to perhaps target this review process as a key intervention and 396 
measure its impact by repeated PPS.10  397 
The third quality indicator referred to parental administration which was highest in Western and 398 
Central Asia, Latin America, Eastern and Southern Europe (>80% of patients on antibiotics). Broad-399 
spectrum antibiotics are commonly administered in these regions (such as third generation 400 
cephalosporins) for which broad-spectrum antibacterial oral equivalents are often lacking. The switch 401 
from intravenous to oral antibiotics has many well-known advantages such as reduction in catheter-402 
related complications, less healthcare costs and earlier hospital discharge. This is recognised as a key 403 
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metric for stewardship processes in hospitals.27, 28 On the other hand, it is not known to what extent 404 
different antibiotic administration routes have an impact on antimicrobial resistance.29  405 
The fourth quality indicator referred to the existence and adherence to antibiotic treatment guidelines. 406 
In Western and Central Asia, local guidelines were not available in 40% of antibiotic prescriptions, 407 
especially for medical prophylaxis in the absence of a clear diagnosis. In one of the African countries, 408 
11% of patients were treated with antibiotics for which the diagnosis was unknown, contrary to 409 
guidelines for LMIC which state that “an appropriate treatment must be preceded by diagnoses that 410 
ensures the correct clinical path”.30 This involves the existence of a clinical microbiology laboratory 411 
and antimicrobial stewardship involvement in for example daily laboratory rounds.31 Guideline 412 
compliance referred only to the choice of drug for therapeutic or prophylactic use. Overall mean 413 
compliance to guidelines reached 77% and was less than 70% in Latin America, Western and Central Asia 414 
and Africa. Next to developing and updating local treatment guidelines, adherence to guidelines may 415 
improve clinical outcome in terms of mortality, as well as treatment duration and length of hospital 416 
stay.32 A recent systematic review and meta-analysis showed that guideline-adherent empirical therapy 417 
was associated with a significant relative risk reduction for mortality of 35%.6 The reason for this 418 
relatively lower level of compliance is uncertain and probably multi-factorial. It may reflect current local 419 
resistance patterns, uncertainty avoidance and fear of failure. Our data provide hospitals/countries with 420 
information to pursue further detailed investigation at country and/or hospital level.  421 
The fifth quality indicator concerned prolonged surgical prophylaxis commonly seen during this PPS and 422 
in line with previous studies conducted in Europe.21 Especially in Southern and Eastern Europe, mean 423 
prolonged surgical prophylaxis was very high (85% and 86.3%). It is well-known that surgical antibiotic 424 
prophylaxis for most indications for >24 hours does not prevent development of post-operative 425 
infections. Instead, it increases the risk of antimicrobial resistance and side effects.33 Evidence showed 426 
that, in the absence of preoperative infection or severe complications, prolonged or surgical 427 
postoperative antibiotic prophylaxis patients is unnecessary.34  428 
 429 
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Study strengths and limitations 430 
 431 
The strength of our study lies in the uniformity of data-collection, the simplicity of the protocol and data 432 
collection templates, the assurance of data quality (data completeness and validation process through 433 
web-based tool), the opportunity for real-time educational feedback of results to participating centres 434 
comparing their results to national and regional results, and the consistency and reproducibility of data.9 435 
Although we had to rely on the participants professionalism and motivation to provide valid data, we 436 
implemented strict online checks to avoid erroneous or incomplete data. Minimal training was required 437 
and most hospitals successfully participated in the Global-PPS with the online supporting materials (e.g. 438 
FAQ), helpdesk support and the online e-learning course (www.futurelearn.com/courses/point-439 
prevalence-surveys) developed by the British Society for Antimicrobial chemotherapy [BSAC]. Thanks to 440 
the simple protocol and tool for data entry and feedback, we successfully included hospitals from low-441 
middle income countries (n=8) and upper middle income countries (n=17, see appendix I). The study, 442 
conducted on a voluntary basis and often carried out with limited resources (financial, IT and 443 
manpower), provided a good utility value for the time commitment (see “evaluation of the 2015 Global-444 
PPS” at www.global-pps.com/documents). It enforces the creation of clinical prescriber buy in, 445 
particularly if the data accrued is fed back to the prescribers,35 the development of a sustainable network 446 
and the construction of a huge database allowing the production of various analyses and publications at 447 
international, regional and local levels. This Global-PPS not only contributes to continued world-wide 448 
awareness about antibiotic use and resistance, but it also helps participants in setting targets to improve 449 
antibiotic prescribing (see examples at www.global-pps.be/dissimination, including several 450 
communications from country networks as well as stand-alone hospitals), thereby driving improved 451 
prescribing behavior.10 452 
 453 
The limitations of this study are inherent to the epidemiological method of a cross-sectional survey 454 
whereby the main purpose is to describe prescribing patterns in hospitals.13 The overall rates provided 455 
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average figures without correcting for patient case mix, disease incidence or prevalence of different 456 
types of infections, variations in resistance levels, institutional factors, differences in climates and 457 
seasons etc., which can all influence antibiotic use patterns. For that reason, one need to be very 458 
cautious in interpreting and comparing the reported prevalence rates.  459 
Although we observed substantial differences in the prevalence of antibiotic prescribing between and 460 
within regions or countries, we are not representative for most of these countries and regions.  For 461 
instance, Northern Europe was mainly presented by the UK, while Western European data included most  462 
Belgian hospitals thanks to the coordination by the Belgian Antibiotic Policy Coordination Committee 463 
(BAPCOC) at federal level.36 Western European results might therefore be biased due to typical Belgian 464 
prescribing practices (e.g. the high use of amoxicillin with beta-lactamase inhibitor). We hope that if in 465 
the future, countries could participate with a representative number of hospitals, which would allow 466 
more meaningful analysis at country and regional level. 467 
 468 
Future considerations 469 
 470 
The Global-PPS was repeated in 2017 with increased participation of additional countries and hospitals. 471 
We focused again on LMIC because it is the only tool available for measuring antibiotic prescribing in 472 
hospitals in these countries, often demonstrating the highest prevalence of antibiotic prescribing and 473 
resistance. We aim to carry out repeated PPS at hospital or ward level (yearly or quarterly) to measure 474 
the impact of antibiotic stewardship interventions. Governments can use the Global-PPS tool to support 475 
the antimicrobial stewardship framework as part of their WHO National Action Plan. Indeed, in some 476 
countries (Saudi Arabia, The Philippines, Belgium), the Global-PPS was endorsed by the Ministries of 477 
Health, inviting many hospitals to participate in the 2017 PPS. The Interagency Coordination Group 478 
(IACG) on AMR of the United Nations could use the Global-PPS tool for international mapping of 479 
antimicrobial prescribing and resistance in hospitals, and for building a sustainable hospital surveillance 480 
framework, focusing on LMIC. The Global-PPS could compliment the Global Antimicrobial Resistance 481 
21 
 
Surveillance System (GLASS) of the WHO.3 Ultimately, we aim to develop appropriate benchmarking 482 
standards, including quantifiable quality targets; but recognizing the significant pitfalls for using these 483 
quantitative data for benchmarking37. Currently, we are developing an educational framework and 484 
training programme for  healthcare professionals working on hospital antibiotic stewardship in LMIC  485 
 486 
Conclusion 487 
 488 
The Global-PPS provided a comprehensive assessment of the prevalence’s of antibiotic use and 489 
resistance internationally, using a simple and user-friendly tool. As such, hospitals from LMIC’s were for 490 
the first time able to measure antimicrobial use patterns. We found substantial differences among 491 
hospitals in the quantity as well as the quality of antibiotic prescribing worldwide. These results will help 492 
hospitals and countries to improve hospital antibiotic prescribing and to define antibiotic stewardship 493 
objectives. 494 
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Table 1. N adult patients on antimicrobial use (%) by region and ward type, year 2015. 
 
UN-region
N 
countries
N 
hospitals
N 
admitted 
patients
Prevalence of 
antimicrobial 
use (%)
N 
admitted 
patients
Prevalence of 
antimicrobial 
use (%)
N 
admitted 
patients
Prevalence of 
antimicrobial 
use (%)
N 
admitted 
patients
Prevalence of 
antimicrobial 
use (%)
N 
admitted 
patients
Prevalence of 
antimicrobial 
use (%)
N 
admitted 
patients
Prevalence of 
antimicrobial 
use (%)
N 
admitted 
patients
Prevalence of 
antimicrobial use 
(%, country range)
Europe 25 215 29663 26.1 18078 33.3 2954 59.2 1947 40.6 1878 52.0 192 74.5 54712 31.9 (23.7-62.0)
Eastern Europe 2 8 778 11.6 1381 33.2 107 67.3 11 9.1 105 30.5 2382 27.4 (23.7-27.8)
Northern Europe 5 36 4959 29.8 2371 37.7 370 55.9 242 49.6 101 53.5 51 60.8 8094 34.4 (29.0-37.8)
Southern Europe 13 53 6443 32.6 5475 40.0 1010 64.1 646 33.6 561 60.2 52 76.9 14187 39.0 (27.2-62.0)
Western Europe 5 118 17483 23.4 8851 28.0 1467 56.0 1048 43.1 1111 49.7 89 80.9 30049 28.1 (25.1-37.1)
Africa 5 12 619 49.9 1101 49.0 64 64.1 1798 50.0 (27.8-74.7)
Asia 15 56 8517 35.0 6912 36.1 1098 59.1 1003 53.0 18088 38.6 (22.4-85.7)
East & Southern Asia 6 29 6644 33.0 5663 34.2 702 65.5 847 54.0 409 46.2 146 86.3 14411 37.2 (29.6-78.5)
Western & Central Asia 9 27 1873 42.0 1249 44.7 396 47.7 156 48.1 3677 43.8 (22.4-85.7)
Oceania 2 9 1781 29.8 604 52.5 76 69.7 46 54.3 2516 37.0 (33.3-38.5)
Americas 6 43 5547 32.2 2707 40.2 992 57.4 294 46.9 80 66.3 9662 37.8 (30.9-44.8)
Latin America 4 19 1942 31.8 1571 37.3 468 55.1 92 28.3 41 65.9 4122 36.8 (32.5-43.4)
Northern America 2 24 3605 32.4 1136 44.2 524 59.4 202 55.4 34 58.8 39 66.7 5540 38.6 (30.9-44.8)
Total 53 335 46127 29.0 29402 35.6 5184 59.0 3298 45.1 2344 51.3 421 77.0 86776 34.4 (22.4-85.7)
Total adult wardsMedical Ward Surgical Ward Intensive Care Unit Haemato-onco ward Pneumology ward Transplant (BMT/solid)
 
Prevalence rates are calculated for and within each ward by region 
Empty cells: No cases or too few cases which are counted in ‘total adult wards’ only 
East & Southern Asia includes Southern, Eastern & South-eastern Asia 
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Northern Europe % 
(n=3536; 5C)
Ceftriaxone 36.3 Amoxicillin/β-lact. inh. 14.4 Ceftriaxone 19.6 Amoxicillin/β-lact. inh. 25.6 Ceftriaxone 19.3 Amoxicillin/β-lact. inh. 7.9 Ceftriaxone 20.2 Cefazolin 10.8 Ceftriaxone 14.4 Levofloxacin 12.8
Ciprofloxacin 9.6 Piperacillin/β-lact. inh. 14.2 Ciprofloxacin 10.3 Piperacillin/β-lact. inh. 8.4 Metronidazole 17.4 Levofloxacin 7.4 Metronidazole 8.3 Ceftriaxone 8.3 Metronidazole 9.5 Piperacillin/β-lact. inh. 11.8
Amoxicillin/β-lact. inh. 9.0 Amoxicillin 8.1 Cefazolin 8.2 Cefazolin 7.1 Ciprofloxacin 10.3 Ceftriaxone 7.3 Ciprofloxacin 7.0 Amoxicillin/β-lact. inh. 8.1 Vancomycin 9.5 Ceftriaxone 11.2
Cefotaxime 8.8 Metronidazole 6.0 Metronidazole 6.5 Ciprofloxacin 7.0 Cefuroxime 9.9 Piperacillin/β-lact. inh. 7.1 Cefuroxime 6.4 Piperacillin/β-lact. inh. 7.8 Cefazolin 6.1 Vancomycin 10.6
Cefazolin 6.6 Doxycycline 5.3 Amoxicillin/β-lact. inh. 6.0 Ceftriaxone 5.0 Amoxicillin/β-lact. inh. 9.6 Cefazolin 6.8 Meropenem 5.5 Metronidazole 7.4 Ciprofloxacin 5.9 Cefazolin 8.0
Cefuroxime 4.8 Ciprofloxacin 5.2 Piperacillin/β-lact. inh. 5.8 Cefuroxime 4.4 Amoxicillin 5.4 Sulfa/trimethoprim 6.1 Piperacillin/β-lact. inh. 5.5 Sulfa/trimethoprim 5.9 Sulfa/trimethoprim 5.4 Ciprofloxacin 6.1
Cefoperazone, comb. 3.4 Flucloxacillin 4.7 Gentamicin 4.6 Sulfa/trimethoprim 3.6 Clindamycin 4.3 Meropenem 5.7 Vancomycin 4.1 Flucloxacillin 5.1 Piperacillin/β-lact. inh. 5.3 Metronidazole 5.5
Metronidazole 2.5 Clarithromycin 4.6 Levofloxacin 3.6 Meropenem 3.5 Levofloxacin 3.1 Cefuroxime 5.4 Cefazolin 4.1 Amoxicillin 4.6 Meropenem 4.8 Meropenem 5.2
Gentamicin 2.0 Gentamicin 4.2 Vancomycin 3.1 Moxifloxacin 3.2 Sulfa/trimethoprim 2.6 Metronidazole 4.2 Amoxicillin/β-lact. inh. 3.3 Doxycycline 4.6 Cefotaxime 4.2 Azithromycin 3.3
Levofloxacin 2.0 Meropenem 4.1 Cefuroxime 2.9 Levofloxacin 3.0 Azithromycin 2.2 Vancomycin 4.2 Azithromycin 3.0 Cefuroxime 4.3 Cefalotin 2.8 Cefepime 3.3
Meropenem 2.0 Teicoplanin 3.5 Meropenem 2.7 Amoxicillin 2.9 Ertapenem 1.6 Ciprofloxacin 3.8 Amoxicillin 3.0 Vancomycin 3.6 Imipenem & enz. inh. 2.8 Sulfa/trimethoprim 2.9
Amikacin 1.7 Cefuroxime 3.4 Amoxicillin 2.5 Vancomycin 2.9 Meropenem 1.3 Ampicillin/β-lact. inh. 3.3 Imipenem & enz. inh. 3.0 Ciprofloxacin 3.3 Clindamycin 2.7 Doxycycline 2.1
Cefepime 1.6 Trimethoprim 2.6 Clindamycin 2.2 Metronidazole 2.6 Ampicillin 1.2 Clindamycin 2.0 Cefotaxime 2.4 Cefalexin 3.2 Amikacin 2.4 Clindamycin 1.7
Ceftriaxone 2.6 Amikacin 2.2 Clindamycin 2.5 Gentamicin 1.0 Cefmetazole 1.9 Gentamicin 2.1 Azithromycin 2.7 Gentamicin 2.3 Cefalexin 1.5
Sulfa/trimethoprim 2.0 Sulfa/trimethoprim 2.0 Flucloxacillin 1.9 Amikacin 0.9 Cefepime 1.7 Cefepime 2.0 Meropenem 2.6 Clarithromycin 2.1 Amoxicillin/β-lact. inh. 1.5
Benzylpenicillin 1.8 Ampicillin 1.7 Ceftazidime 1.5 Cefoperazone, comb. 1.5 Colistin 1.7 Benzylpenicillin 1.9 Colistin 1.9 Linezolid 1.5
Vancomycin 1.5 Imipenem & enz. inh. 1.6 Clarithromycin 1.4 Clarithromycin 1.4 Ampicillin 1.5 Roxithromycin 1.9 Ampicillin 1.8 Amoxicillin 1.4
Clindamycin 1.2 Ceftazidime 1.3 Temocillin 1.3 Cefcapene 1.4 Sulfa/trimethoprim 1.4 Gentamicin 1.5 Cloxacillin 1.8
Cefalexin 1.0 Azithromycin 1.1 Azithromycin 1.3 Teicoplanin 1.3 Ampicillin, comb. 1.4 Cefaclor 1.5 Ceftazidime 1.6
Cefepime 1.0 Cefepime 1.1 Azithromycin 1.2 Moxifloxacin 1.4 Clindamycin 1.4 Ertapenem 1.4
Ertapenem 0.8 Nitrofurantoin 1.1 Ampicillin 1.1 Amikacin 1.3 Levofloxacin 1.2
Clarithromycin 0.8 Ceftazidime 1.0 Ceftazidime 1.0 Azithromycin 1.0
Amoxicillin 0.9 Ceftizoxime 0.9
Imipenem & enz. inh. 0.9
Gentamicin 0.9
Cefotiam 0.8
Amikacin 0.7
Cefditoren 0.6
Cloxacillin 0.6
Doxycycline 0.6
Minocycline 0.6
Oceania %                      
(n=1226, 2C)
Latin America %                    
(n=2170, 4C)
Northern America %               
(n=2752, 2C)
Eastern Europe %                        
(n=708; 2C)
Southern Europe  %                   
(n=6837; 12C)
Western Europe %                    
(n=9485, 5C)
Africa %                                  
(n=1213, 4C)
East & Southern Asia % 
(n=6781, 6C)
Western & Central Asia % 
(n=2084, 9C)
 
Table 2. Most Prescribed Antibiotics (ATC J01; 5th level) to adult inpatients by UN Region, ranked at overall drug utilization 90% (DU90%), year 2015. 
Grey lines provides drug utilization up to 75% (DU75%) by UN Region; C=countries 
East & Southern Asia includes Southern, Eastern & South-eastern Asia 
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Diagnosis code
Eastern 
Europe % 
(n=646 
patients)
Northern 
Europe % 
(n=2791 
patients)
Southern 
Europe % 
(n=5452 
patients)
Western 
Europe % 
(n=8414 
patients)
Africa        
%            
(n=870 
patients)
East & 
Southern 
Asia % 
(n=5402 
patients)
Western 
& Central 
Asia % 
(n=1626 
patients)
Oceania 
%     
(n=967 
patients)
Latin 
America 
% 
(n=1554 
patients)
Northern 
America 
% 
(n=2139 
patients)
Total      
%      
(n=29861 
patients)
LRTI 15.2 28.2 14.3 23.3 10.3 16.2 14.8 19.0 16.5 21.1 19.2
Skin & Soft Tissue 13.5 9.1 6.7 8.0 16.2 8.2 7.9 15.6 12.5 11.6 9.0
Intra-abdominal 1.2 8.3 5.6 7.1 3.8 7.8 5.2 9.1 10.2 7.4 7.0
Lower UTI 0.5 6.7 4.3 8.1 2.4 3.5 4.6 8.5 5.5 11.2 6.0
Upper UTI 4.6 5.9 4.3 4.9 1.4 4.5 5.3 3.6 6.0 4.3 4.7
Proph Bone Joint 7.6 2.4 6.3 4.7 6.6 4.4 3.1 6.1 4.1 3.5 4.7
URTI (Bronchitis) 5.6 3.5 4.5 7.3 0.7 1.1 5.2 3.0 1.8 2.9 4.2
Proph Gastro-intestinal 6.3 1.8 8.1 2.4 2.8 4.3 8.2 1.7 5.3 1.7 4.2
Med Proph in general 2.8 2.3 5.0 2.7 2.9 5.9 1.2 5.0 3.9 3.5 3.8
Unknown 0.8 3.5 2.7 2.9 11.4 3.0 2.0 1.9 1.7 4.0 3.1
Proph Obstetrics/Gyn. 3.9 2.5 4.4 0.9 9.8 4.4 3.8 1.3 2.9 2.6 3.0
Bone Joint infection 3.4 2.2 1.6 3.5 3.0 2.4 3.3 3.7 2.6 3.4 2.8
Sepsis 0.2 3.9 2.1 2.3 3.8 2.8 4.5 0.7 2.6 3.8 2.7
Proph UTI 5.3 2.0 3.4 2.8 1.7 1.5 4.5 2.6 2.8 1.3 2.6
Gastro-intestinal 4.8 1.5 2.3 2.3 2.4 2.3 4.4 1.4 1.7 2.9 2.4  
Table 3. Top 10 most recorded reasons to treat adult inpatients with at least one antibacterial for systemic 
use (ATC J01), year 2015.  
Patients recorded with more than one diagnoses will be counted according to the number of diagnosis, 
Patients not treated by antibacterials for systemic use (J01), but treated with other antimicrobials (eg 
antimalarials) are not included in this table.   
East & Southern Asia includes Southern, Eastern & South-eastern Asia 
LRTI= Pneumonia or LRTI (lower respiratory tract infections); Skin & Soft Tissue: Cellulitis, wound including 
surgical site infection, deep soft tissue not involving bone e.g., infected pressure or diabetic ulcer, abscess; 
Intra-abdominal= Intra-abdominal sepsis including hepatobiliary, intra-abdominal abscess etc.; Lower UTI= 
Lower urinary tract infection, cystitis; Upper UTI=upper urinary tract infection including catheter related 
urinary tract infection, pyelonephritis; Proph Bone Joint=Prophylaxis for SST, for plastic or orthopaedic surgery 
(Bone or Joint); URTI (bronchitis)= Acute Bronchitis or exacerbations of chronic bronchitis; Proph Gastro-
intestinal= Surgery of the Gastro-Intestinal tract, liver or biliary tree, GI prophylaxis in neutropaenic patients or 
hepatic failure , Med Proph in general=Drug is used as Medical Prophylaxis in general, without targeting a 
specific site; Unknown=Completely Unknown Indication; Proph Obstretrics/Gyn.= Prophylaxis for Obstetric or 
Gynaecological surgery; Bone joint Infection: Septic arthritis (including prosthetic joint), osteomyelitis, Sepsis= 
sepsis, sepsis syndrome or septic shock with no clear anatomic site, Proph UTI= Prophylaxis for urological 
surgery (SP) or recurrent Urinary Tract Infection (MP); Gastro-intestinal = Gastro intestinal infections 
(salmonellosis, Campylobacter, parasitic, C.difficile, etc.).  
 
  
Total N 
antibiotics 
(J01)
Antibiotics 
for a CAI %
Targeted 
prescribing 
for a CAI %
Antibiotics 
for a HAI %
Targeted 
prescribing 
for a HAI %
Eastern Europe 708 46.5 12.2 11.6 34.1 23.7 17.5
Northern Europe 3536 56.3 14.1 25.1 20.4 5.8 9.5
Southern Europe 6837 36.7 16.6 20.6 41.3 8.2 29.2
Western Europe 9485 51.0 27.1 28.3 43.4 5.9 12.0
Africa 1213 57.4 19.5 9.5 33.9 3.5 23.2
East & Southern Asia 6781 36.9 22.2 27.7 31.7 9.8 21.3
Western & Central Asia 2084 44.8 13.4 20.9 36.8 7.7 23.2
Oceania 1226 53.3 23.1 23.6 38.4 7.6 12.6
Latin America 2170 41.4 19.1 34.9 44.1 5.6 16.0
Northern America 2752 52.2 22.8 26.1 31.2 5.1 8.6
Total 36792 45.6 20.9 25.2 36.9 7.4 17.8
Prophylactic useTherapeutic use
Therapeutic use Antibiotics 
for Medical 
Prophylaxis 
(%)
Antibiotics 
for Surgical 
Prophylaxis 
(%)
 
Table 4. Antibiotic use (ATC J01) by indication and type of treatment (targeted versus empiric) for adult inpatients 
by region, year 2015. 
CAI= Community Acquired Infection; HAI=Hospital Acquired Infection. 
Overall, 486 antibiotics were recorded with ‘another’ indication; 1009 antibiotics with unknown indication; these 
are not listed in the table. 
East & Southern Asia includes Southern, Eastern & South-eastern Asia 
 
  
REGION
N 
treated 
patients
N 
antimicrobial 
prescriptions
N antibiotic 
(J01) 
prescriptions
N patients 
with 
targeted 
treatment
N patients with 
targeted 
treatment 
against resistant 
organisms
Targeted 
treatment§ 
% patients
% patients 
treated with 
ABs targeting 
resistant 
organisms
Reason in 
notes*                 
%
Stop/review 
date 
documented*  
%
Parenteral 
RoA°                    
% patients
% antibiotic 
prescriptions 
for which 
guidelines were 
available°°
% antibiotic 
prescriptions 
compliant to 
local 
guidelines+
% of antibiotic 
prescriptions 
for which no 
guidelines were 
available++
Eastern Europe 653 747 708 51 42 7.8 6.4 64.3 50.5 87.6 79.8 85.7 19.2
Northern Europe 2783 3880 3536 396 80 14.2 2.9 81.4 51.6 62.2 90.0 83.4 6.5
Southern Europe 5534 7674 6837 838 292 15.1 5.3 69.5 29.1 80.0 60.5 70.8 29.6
Western Europe 8458 10612 9485 2204 469 26.1 5.5 80.5 40.3 64.0 81.0 78.7 10.1
Africa 899 1502 1213 131 25 14.6 2.8 70.4 36.6 62.7 49.5 67.9 26.7
East & Southern Asia 5363 7607 6781 938 287 17.5 5.4 74.6 43.5 71.8 76.4 81.5 21.4
Western & Central Asia 1612 2252 2084 236 153 14.6 9.5 72.8 19.8 85.2 53.4 66.3 40.5
Oceania 932 1411 1226 218 63 23.4 6.8 85.1 27.0 60.5 87.4 73.2 11.7
Latin America 1518 2403 2170 403 231 26.5 15.2 81.4 40.3 84.4 76.5 64.1 19.9
Northern America 2139 3125 2752 511 127 23.9 5.9 84.9 39.6 73.1 77.3 85.8 18.5
Grand Total 29891 41213 36792 5926 1769 19.8 5.9 76.9 38.3 71.4 74.3 77.4 19.2
Denominators Antimicrobial/Antibiotic quality indicators
 
Table 5. Overview of antimicrobial/antibiotic quality indicators for adult inpatients by region, year 2015. 
§ % patients receiving at least one antibiotic for systemic use (ATC J01), selection has been made for therapeutic antibiotic use only (HAI and CAI). Calculation= N patients with 
targeted treatment/N treated patients.  
* Including all antimicrobials. Denominator=N antimicrobial prescriptions 
°  % patients receiving at least one parenteral antibiotic for systemic use (ATC J01). Denominator=N treated patients 
°° % prescriptions for which guidelines were available refers to the antibiotic choice (not route, dose, duration) and is calculated as compliance to guidelines Yes and No/ 
compliance with local guidelines Yes and No + those for which no local guidelines for the specific indication were available (not applicable) + those not indicated (NI) where 
information is lacking because the indication is unknown 
+ Denominator used is “all antibiotic (J01) prescriptions for which guidelines were available”  
++ Denominator used are all antibiotic (J01) prescriptions 
ABs=antibiotics for systemic use (ATC J01) 
East & Southern Asia includes Southern, Eastern & South-eastern Asia 
  
N patients 
received a 
targeted 
treatment*
N patients with 
targeted treatment 
against resistant 
organisms
% pat 
MRSA
% pat 
MRCoNS
% pat 
VRE
% pat 
ESBL
% pat 3rd 
gen cep
% pat 
CRE
% pat ESBL 
non 
fermenter
% pat CR 
non 
fermenter
% pat 
other 
MDRO
Eastern Europe 53 42 7.5 1.9 37.7 5.7 15.1 20.8 3.8
Northern Europe 435 80 5.3 0.7 1.6 6.0 0.9 0.2 0.2 1.8 2.3
Southern Europe 1021 292 5.0 2.2 2.9 8.4 1.5 2.1 2.8 3.6 4.9
Western Europe 2472 469 3.4 1.8 0.2 7.1 3.0 0.4 0.5 0.6 2.8
Africa 170 25 1.2 0.6 5.3 0.6 1.8 2.4 2.9
East & Southern Asia 1070 287 6.2 2.8 0.9 6.5 3.6 2.1 1.7 3.6 2.4
Western Central Asia 266 153 9.8 1.1 0.8 13.9 3.8 3.0 6.8 7.5 15.0
Oceania 227 63 4.8 1.8 1.8 6.6 2.6 0.4 11.5 1.8 0.9
Latin America 450 231 10.4 4.9 1.3 19.1 4.4 4.0 2.4 1.1 4.4
Northern America 586 127 7.8 2.0 1.4 4.3 2.9 1.4 5.1 3.1
Total 6750 1769 5.3 2.1 1.1 8.1 2.8 1.2 2.0 2.6 3.6  
Table 6. Prevalence rate of adult inpatients (%) receiving a targeted antibiotic (ATC J01) treatment by region and resistance profile of the organism, year 2015. 
* denominator = number of patients receiving a targeted treatment  
Targeted treatment = based upon microbiological result. Microbiology result can be any culture and/or sensitivity result from a relevant clinical (e.g., blood, sputum, etc.,) [but 
not screening] specimen as well as any other microbiology result like for example Legionella Urinary Antigen.  
If the treatment was based on microbiology data, participants could report whether the treatment choice was based on one of the following 9 micro-organisms: 
MRSA=meticillin-resistant Staphylococcus aureus, MRCoNS=meticillin-resistant coagulase-negative staphylococci, VRE=vancomycin-resistant enterococci, 
ESBL=Enterobacteriaceae producing extended-spectrum beta-lactamase, 3rd gen cep=3rd generation cephalosporin resistant Enterobacteriaceae non-ESBL producing or ESBL 
status unknown, CRE=carbapenem-resistant Enterobacteriaceae, ESBL non-fermenter= ESBL-producing non-fermenter Gram-negative bacilli, CR non-fermenter=carbapenem-
resistant non-fermenter Gram-negative bacilli, Other MDRO=other multi-drug resistant organisms 
 
Note: a patient can be counted twice depending on the number of targeted antibiotics administered for more than one resistant micro-organism. 
East & Southern Asia includes Southern, Eastern & South-eastern Asia 
  
Figure 1. Proportion of prescribed antibiotics for systemic use (ATC4 level, N=9,261) for a HAI among adult 
inpatients by region, year 2015 
 
Not colored striped part of stacked bar represents other antibacterial subgroups 
N=number of reported antibiotics for systemic use at regional level 
East & Southern Asia includes Southern, Eastern & South-eastern Asia 
 
  
Figure 2. Proportion of prescribed antibiotics for systemic use (ATC4 level, N=13,226) for a CAI among adult 
inpatients by region, year 2015 
 
Not colored striped part of stacked bar represents other antibacterial subgroups 
N=number of reported antibiotics for systemic use at regional level 
East & Southern Asia includes Southern, Eastern & South-eastern Asia 
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